Company news

Spyre Therapeutics, Inc. news in 2025

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 3, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

November 3, 2025

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

October 28, 2025

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

October 23, 2025

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

October 14, 2025

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

October 12, 2025

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 4, 2025

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

September 14, 2025

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

September 8, 2025

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 16, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 15, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

May 27, 2025

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

May 4, 2025

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

March 26, 2025

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

February 26, 2025

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

February 24, 2025

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

February 18, 2025

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

January 12, 2025

Decks in 2025